Ashland Global (ASH)

Q: What's priced into Ashland Global (ASH) stock?

The valuation is described as a premium to peers, and the model points to a small expectations gap, with potential change driven by a re-rating. The market pricing is tagged as justified with low fragility, so the evidence does not suggest that the thesis relies on an unusually fragile set of expectations.

Q: What does the Ashland Global (ASH) outlook hinge on?

The next call is an important swing factor: a guidance cut would weaken the thesis, while continued delivery against reaffirmed goals would support it. Sector conditions also matter; results and guidance from LIN, SHW, and ECL may signal whether the materials-sector tailwind strengthens or fades. Recent M&A agreements and a new financial obligation are additional developments to monitor, though their effect is not clear from the evidence.

NYSEMaterialsChemicals - SpecialtySnapshot 2026-10-23

$72.99-0.79%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Ashland Global’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2027 · Q1
Revenue	—	403.61M
EPS	—	0.34
FY 2026 · Annual
Revenue	$1.84B–$1.87B	—
EBITDA	$385M–$400Mnon-GAAP	—
FY 2027 · Annual
Revenue	—	1.93B
EPS	—	4.298
FY 2028 · Annual
Revenue	—	2B
EPS	—	4.946

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve $385-$400 million Adjusted EBITDA in fiscal 2026	Profit margins target adjusted EBITDA near $385-$400 million.	Intact	adjusted EBITDA falls below $385 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Adjusted EBITDA improved from $58 million in 2026-Q1 to $109 million in 2026-Q3, showing recovery despite operational challenges. Management has consistently reaffirmed the $385-$400 million full-year Adjusted EBITDA guidance, reflecting mixed but improving delivery. Delivery assessment Oct 24, 2026
Maintain 50% free cash flow conversion of Adjusted EBITDA	Free cash flow conversion is focused at 50% of adjusted EBITDA.	Intact	free cash flow conversion falls below 40% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Ongoing Free Cash Flow increased from $26 million in 2026-Q1 to $103 million in 2026-Q3, with conversion rates above 50%. Capital expenditures are guided at approximately $90 million for fiscal 2026. Management is delivering on disciplined cash flow conversion and capital allocation. Delivery assessment Oct 24, 2026
Achieve $1.835-$1.87 billion revenue in fiscal 2026	Ashland aims to grow revenue to about $1.85 billion in fiscal 2026.	Intact	annual revenue falls below $1.835 billion in FY26	Revenue: $497M FY2026-Q3; GAAP. Published target: >= $1.835 billion and <= $1.87 billion. Target period is not explicitly aligned with this observation. Source published Jul 29, 2026497,000,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 4a056b72-27cd-43f2-a521-f931c50bd1dd. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Revenue grew from $386 million in 2026-Q1 to $497 million in 2026-Q3, a 29% increase. Management has consistently reaffirmed the full-year fiscal 2026 sales guidance of $1,835 to $1,870 million, indicating delivery on this growth priority. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-09-30 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue$2.00B

$2.01B → $2.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-10-01	Unavailable	$2,008,228,904	2 / 8
2026-10-02	Unavailable	$2,008,228,904	2 / 8
2026-10-03	Unavailable	$2,008,228,904	2 / 8
2026-10-04	Unavailable	$2,008,228,904	2 / 8
2026-10-05	Unavailable	$2,008,228,904	2 / 8
2026-10-06	Unavailable	$2,004,807,563	2 / 8
2026-10-07	Unavailable	$2,004,807,563	2 / 8
2026-10-08	Unavailable	$2,004,807,563	2 / 8
2026-10-09	Unavailable	$2,004,807,563	2 / 8
2026-10-10	Unavailable	$2,004,807,563	2 / 8
2026-10-11	Unavailable	$2,004,807,563	2 / 8
2026-10-12	Unavailable	$2,004,807,563	2 / 8
2026-10-13	Unavailable	$2,004,807,563	2 / 8
2026-10-14	Unavailable	$2,004,807,563	2 / 8
2026-10-15	Unavailable	$2,004,807,563	2 / 8
2026-10-16	Unavailable	$2,004,807,563	2 / 8
2026-10-17	Unavailable	$2,004,807,563	2 / 8
2026-10-18	Unavailable	$2,002,682,563	2 / 8
2026-10-19	Unavailable	$2,002,682,563	2 / 8
2026-10-20	Unavailable	$2,002,682,563	2 / 8
2026-10-21	Unavailable	$2,002,682,563	2 / 8
2026-10-22	Unavailable	$2,002,622,047	2 / 8
2026-10-23	Unavailable	$2,002,622,047	2 / 8
2026-10-24	Unavailable	$2,002,622,047	2 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	9	4
2026-06-01	9	3
2026-07-01	9	3
2026-08-01	9	3
2026-09-01	9	3
2026-10-01	9	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Wells FargoOct 16

$75.00New observation · no comparable prior

UBSOct 5 · prior Jul 30

$83.00 → $80.00-3.6%

$0$45.65$91.30

0 raises · 1 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve $385-$400 million Adjusted EBITDA in fiscal 2026Direct metric needs a verified mapping
Maintain 50% free cash flow conversion of Adjusted EBITDADirect metric needs a verified mapping
Achieve $1.835-$1.87 billion revenue in fiscal 2026Revenue: $497M

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

0.9%Typical daily move · historical

Downside history

-24.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Ashland Global outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

ASH is a recovery-oriented materials business, with recent results showing improvement but earnings still classified as loss-making in the evidence. The long-term thesis is intact, while the signal has shifted from cautious to mixed; confidence in the assessment is medium.

What's priced into Ashland Global

The valuation is described as a premium to peers, and the model points to a small expectations gap, with potential change driven by a re-rating. The market pricing is tagged as justified with low fragility, so the evidence does not suggest that the thesis relies on an unusually fragile set of expectations.

What the fundamentals likely do

Near-term, management has reaffirmed fiscal 2026 revenue and adjusted EBITDA guidance. Revenue, adjusted EBITDA, and free cash flow improved between the first and third quarters, though delivery against the EBITDA goal remains mixed and recent earnings misses are a risk. Over the multi-year view, consistent cash flow conversion supports execution, while the sector backdrop remains a headwind.

What Ashland Global hinges on

The next call is an important swing factor: a guidance cut would weaken the thesis, while continued delivery against reaffirmed goals would support it. Sector conditions also matter; results and guidance from LIN, SHW, and ECL may signal whether the materials-sector tailwind strengthens or fades. Recent M&A agreements and a new financial obligation are additional developments to monitor, though their effect is not clear from the evidence.

Bottom line

Over the next 1 to 3 years, ASH presents a mixed recovery thesis: cash flow and recent operating measures have improved, but earnings misses, mixed EBITDA delivery, and a sector headwind leave meaningful execution risk. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.